Technical Analysis for ALIM - Alimera Sciences, Inc.

Grade Last Price % Change Price Change
grade B 1.08 3.85% 0.04
ALIM closed down 1.89 percent on Friday, March 22, 2019, on 89 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical ALIM trend table...

Date Alert Name Type % Chg
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.85%
Mar 22 Inside Day Range Contraction 3.85%
Mar 22 Below Lower BB Weakness 3.85%
Mar 22 Lower Bollinger Band Touch Weakness 3.85%
Mar 21 20 DMA Resistance Bearish 1.89%
Mar 21 50 DMA Support Bullish 1.89%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.89%
Mar 21 Spinning Top Other 1.89%
Mar 21 Wide Range Bar Range Expansion 1.89%
Mar 21 Below Lower BB Weakness 1.89%

Older signals for ALIM ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.
Medicine Chemistry Biopharmaceutical Diseases Disease Organ Systems Diabetes Age Related Macular Degeneration Fluid Dynamics Glucocorticoids Macular Edema Blindness Diabetic Macular Edema Diabetic Retinopathy Pregnanes Retina Alimera Sciences Diketones Retinal Vein Occlusion
Is ALIM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.21
52 Week Low 0.718
Average Volume 107,838
200-Day Moving Average 0.9856
50-Day Moving Average 1.0227
20-Day Moving Average 1.1358
10-Day Moving Average 1.123
Average True Range 0.0567
ADX 21.76
+DI 13.0457
-DI 22.2937
Chandelier Exit (Long, 3 ATRs ) 1.0399
Chandelier Exit (Short, 3 ATRs ) 1.1801
Upper Bollinger Band 1.2056
Lower Bollinger Band 1.066
Percent B (%b) -0.19
BandWidth 12.290896
MACD Line 0.0139
MACD Signal Line 0.0328
MACD Histogram -0.0188
Fundamentals Value
Market Cap 71.81 Million
Num Shares 69 Million
EPS -0.39
Price-to-Earnings (P/E) Ratio -2.67
Price-to-Sales 2.38
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.09
Resistance 3 (R3) 1.09 1.08 1.08
Resistance 2 (R2) 1.08 1.07 1.08 1.07
Resistance 1 (R1) 1.06 1.06 1.06 1.06 1.07
Pivot Point 1.05 1.05 1.05 1.05 1.05
Support 1 (S1) 1.03 1.04 1.03 1.03 1.01
Support 2 (S2) 1.02 1.03 1.02 1.01
Support 3 (S3) 1.00 1.02 1.00
Support 4 (S4) 1.00